Combination IO study in melanoma stopped

A Phase 3 trial in which a combination of Keytruda (pembrolizumab) and the IDO1 inhibitor epacadostat were being studied in patients with metastatic melanoma has been stopped after failing to show a benefit in progression-free survival, according to Incyte Corp and Merck & Co Inc.

Full text available to subscribers only. Click here for information on subscribing to MedNous.


United States